GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Precigen Inc.
PGEN (formerly Precigen) is a biotech company developing cell and gene therapies. Its stock price is highly volatile, reflecting investor confidence in its technology platform. The chart tells the story of the hopes and risks associated with developing breakthrough treatments.
Share prices of companies in the market segment - Pharma immune
Precigen is a biotech company developing cell and gene therapies. This is its core segment. We classify it as part of the Pharma-Immune sector, and the chart below reflects the dynamics of this cutting-edge and high-risk field of biotechnology.
Broad Market Index - GURU.Markets
Precigen is a biotech company developing next-generation gene and cell therapies for the treatment of cancer and autoimmune diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this innovative company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PGEN - Daily change in the company's share price Precigen Inc.
The volatility of Precigen, a biotech company specializing in cell therapy, reflects the sector's high risks. Change_co is an immediate reaction to news about clinical trials. This indicator forms the basis for immunotherapy sector analysis using System.GURU.Markets tools.
Daily change in the price of a set of shares in a market segment - Pharma immune
Precigen, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. A comparison with PGEN, a gene therapy platform, helps us assess it as a high-risk, clinical-data-dependent asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Precigen is a biopharmaceutical company developing cell and gene therapies. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Precigen's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Precigen Inc.
Precigen is a biotech company working in the field of immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Precigen, Inc. is a biotech company developing gene and cell therapies. Its platform enables the creation of programmable drugs. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough potential rather than current financial performance, which is typical for this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Precigen is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Precigen Inc.
Precigen, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its innovative cell and gene therapies, the success of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Precigen is a biotech company developing gene and cell therapies for the treatment of cancer and autoimmune diseases. Its valuation is based on the potential of its scientific platform and clinical trial data. The immunotherapy sector chart clearly demonstrates investor appetite for the high-risk but potentially breakthrough technologies Precigen is developing.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working at the cutting edge of science, such as cell therapy, often move independently of the market. The chart below shows the overall sentiment. Is Precigen, Inc. living in a world of its own, where development news trumps overall market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Precigen Inc.
Precigen, a biotech company developing cell and gene therapies, exhibits high volatility. Weekly stock performance hinges on news about the progress of clinical trials of its innovative platforms, with any development potentially dramatically changing the company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Precigen, like other early-stage biotech companies, often moves in response to overall sector sentiment. The chart allows you to compare its volatility with the industry's overall performance, distinguishing reactions to general news from sharp movements driven by specific clinical trial data.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Precigen is a biotech company developing cell and gene therapies. Its shares exist in a world of their own, where research data is king. The chart shows that Precigen's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
PGEN - Market capitalization of the company Precigen Inc.
Precigen's stock price is a financial bet on the programming of living cells. The market capitalization of this biotech company, which develops platforms for creating "living drugs" (gene and cell therapies), reflects faith in its cutting-edge technologies. Its volatility reflects the risks and enormous potential in one of the most complex areas of modern medicine.
PGEN - Share of the company's market capitalization Precigen Inc. within the market segment - Pharma immune
Precigen is a biotech company developing next-generation gene and cell therapies. Its market capitalization reflects the potential of its UltraCAR-T platform and other innovative approaches to cancer treatment. The chart shows how much investors are betting on its scientific breakthroughs in the fight against serious diseases.
Market capitalization of the market segment - Pharma immune
Precigen is a biotech company developing cell and gene therapies. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' hopes that Precigen's cutting-edge technologies will lead to new cancer treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Precigen is a biotech company developing gene and cell therapies. Its market cap is a bet on the future of personalized medicine. Its volatile price reflects both the high potential of its platform and the risks associated with lengthy and expensive clinical trials.
Book value capitalization of the company, segment and market as a whole
PGEN - Book value capitalization of the company Precigen Inc.
Precigen is a biotech company, and its book value represents R&D capital. The chart below shows its financial resources, not its manufacturing facilities. Its level is an indicator of the company's ability to fund its cutting-edge research in gene and cell therapy.
PGEN - Share of the company's book capitalization Precigen Inc. within the market segment - Pharma immune
Precigen is a biotech company developing gene and cell therapies. Its core capital is intellectual property. The share of physical assets will reflect its R&D-focused model, where the company's primary tangible assets are high-tech laboratories rather than factories.
Market segment balance sheet capitalization - Pharma immune
Precigen is a biotechnology company developing cell and gene therapies. Its core assets are its cutting-edge scientific platform and intellectual property. A book value chart shows that its value is based on intangible assets, which is typical for companies at the forefront of biomedical innovation.
Book value of all companies included in the broad market index - GURU.Markets
Precigen's assets comprise a platform for developing next-generation cell and gene therapies. The company's book value reflects its production capacity for creating dormant vectors (UltraCAR-T) and its R&D laboratories. This provides the foundation for developing safer and more accessible cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Precigen Inc.
Precigen is a biotechnology company developing cell and gene therapies. Its book value is cash. Its market capitalization is the valuation of its cutting-edge UltraCAR-T technology platform and other innovative approaches to cancer treatment. Investors are paying for the potential of revolutionary science.
Market to book capitalization ratio in a market segment - Pharma immune
Precigen, Inc. is a biotech company developing gene and cell therapies. Its value lies in its scientific platform. The chart shows how market expectations for its breakthrough technologies compare to its minimal tangible assets. It's a bet on the future of personalized medicine.
Market to book capitalization ratio for the market as a whole
Precigen is a biotech company developing gene and cell therapies. Its value is based almost entirely on the potential of its UltraCAR-T research platform. The chart demonstrates how the market valuation reflects investor faith in this breakthrough technology, creating a significant gap with the current book value of its assets.
Debts of the company, segment and market as a whole
PGEN - Company debts Precigen Inc.
Precigen, a biotech company developing cell and gene therapies, uses debt to finance its cutting-edge clinical programs. This chart shows how the company raises capital to advance its innovative approaches to cancer treatment. For a research-stage company, debt is a vital resource for achieving scientific goals.
Market segment debts - Pharma immune
Precigen is a biotech company developing gene and cell therapies. For companies at the cutting edge of science, with long and expensive development cycles, raising capital, including debt, is vital. The chart shows how Precigen's financial strategy compares to the high risk and potential of its innovative platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Precigen Inc.
Precigen is a biotech company developing gene and cell therapies. Its UltraCAR-T platform is the foundation for developing cancer treatments. This chart shows the company's financial strategy during the research phase. Being debt-free is vital, as it gives Precigen the freedom to conduct costly clinical trials without pressure from creditors.
Market segment debt to market segment book capitalization - Pharma immune
Precigen is a biotech company developing gene and cell therapies. Its approach is based on creating "programmed" drugs to treat cancer and autoimmune diseases. This chart shows the overall debt burden in the sector. It helps understand how Precigen finances its cutting-edge, but very expensive and risky, scientific platforms.
Debt to book value of all companies in the market
Precigen, a biotech company developing cutting-edge gene therapy, requires massive capital investment. This chart shows the overall market leverage, reflecting risk appetite. It helps understand how easy or difficult it is for such companies to raise capital for their revolutionary but risky projects at different stages of the economic cycle.
P/E of the company, segment and market as a whole
P/E - Precigen Inc.
Precigen develops gene and cell therapies to treat cancer and other diseases. This chart, like many biotech companies, is a measure of hope. Its value reflects investors' belief in the breakthrough potential of its UltraCAR-T technology platform and other developments, which, if successful, could generate billions in future revenues.
P/E of the market segment - Pharma immune
Precigen is a biotech company in the gene and cell therapy sector. This chart shows the average P/E ratio for this leading industry. Comparing the company's P/E to this benchmark allows us to judge how highly the market values its UltraCAR-T scientific platform compared to technologies being developed by other biotech companies.
P/E of the market as a whole
Precigen is a biotech company developing gene and cell therapies. Its platform enables the creation of "living drugs" for the treatment of cancer and autoimmune diseases. The company's valuation is based on the potential of its technologies. This chart shows the market's risk appetite. It helps us understand whether the market believes in the breakthrough potential of Precigen's platform and how its valuation reacts to news from the lab.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Precigen Inc.
Precigen is a biotech company developing gene and cell therapies. This chart reflects investor expectations for its innovative UltraCAR-T platform for cancer treatment. The company's valuation is based on clinical success projections and the potential of its technology to offer faster and more affordable treatment than existing CAR-T therapies.
%20P%2FE%20Precigen%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Precigen-Inc.&v=1772603670216 "Chart of the company's future (projected) P/E Precigen Inc.")
Future (projected) P/E of the market segment - Pharma immune
Precigen is a biotech company developing gene and cell therapies. This chart compares the company's future profitability expectations with those of the biopharmaceutical sector. It reflects investor optimism about its multifunctional UltraCAR-T platform and other innovative approaches to treating cancer and autoimmune diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772603670248 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Precigen is a biotech company developing gene and cell therapies. For a company operating at the cutting edge of science, access to funding is critical. The overall market optimism illustrated by this chart drives investor willingness to invest in high-risk but potentially revolutionary medical technologies, which will determine Precigen's future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772603670251 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Precigen Inc.
Precigen is a biotechnology company developing gene and cell therapies. Its financial position is characterized by significant investments in research and the absence of commercial products. This chart illustrates the company's financial trajectory during the R&D stage, where value is created through progress in clinical trials rather than through ongoing profits.
Profit of companies in the market segment - Pharma immune
Precigen is a biotech company developing gene and cell therapies. Its UltraCAR-T platform aims to create personalized cancer treatments. This graph, showing overall sector profitability, reflects the potential of this cutting-edge technology. Success in Precigen's clinical programs could lead to breakthrough treatments and have a profound impact on the entire industry.
Overall market profit
Precigen is a biotech company developing gene and cell therapies. Its UltraCAR-T platform promises to create personalized cancer treatments faster and more affordably. The company's value lies in its scientific potential and its ability to change the paradigm in oncology, making it dependent on clinical success rather than market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Precigen Inc.
Precigen is a biotechnology company developing gene and cell therapies. The future revenue projections you see are speculative and depend on the success of its clinical programs. Analysts' expectations are based on research data and the potential of its innovative UltraCAR-T platform for cancer treatment.
%20profit%20of%20the%20company%20Precigen%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Precigen-Inc.&v=1772603670516 "Graph of future (projected) profit of the company Precigen Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Precigen develops and commercializes next-generation gene and cell therapies. The company's UltraCAR-T® platform aims to create safer and more effective cancer treatments. This chart shows revenue projections for the immunotherapy segment, allowing you to assess how Precigen's cutting-edge technology compares to financial expectations for this revolutionary field of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772603670634 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Precigen is a biotechnology company developing gene and cell therapies. Its future depends on scientific breakthroughs and clinical trial results. This economic outlook is important for Precigen in terms of access to capital. During periods of market optimism, investors are more inclined to fund long-term and risky R&D projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772603670669 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Precigen Inc.
Precigen is a biotech company developing gene and cell therapies. This chart, plotting market capitalization against minimal or no revenue, reflects pure expectations. It demonstrates the high valuation investors place on its cutting-edge technology platform, believing in its potential to create breakthrough treatments for cancer and other diseases.
P/S market segment - Pharma immune
Precigen is a gene and cell therapy biotechnology company developing innovative treatments for cancer and autoimmune diseases. Its UltraCAR-T® platform aims to create more effective and affordable treatments. This chart shows the market premium the biotech sector is willing to pay for revenue, highlighting the anticipated breakthrough potential of Precigen's platform.
P/S of the market as a whole
Precigen, Inc. is a biopharmaceutical company developing gene and cell therapies using its UltraCAR-T platform for cancer treatment. The company's valuation is based on the potential of its innovative approaches. This chart, showing the average market revenue estimate, emphasizes that investors are looking at Precigen's future prospects, not current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Precigen Inc.
Precigen is a biotechnology company developing gene and cell therapies. For a clinical-stage company, this chart shows the market's estimate of its potential future revenue. It reflects investor confidence in its innovative platforms, including UltraCAR-T technology, and its success in treating cancer and autoimmune diseases.
%20P%2FS%20Precigen%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Precigen-Inc.&v=1772603671012 "The graph of the company's future (projected) P/S Precigen Inc.")
Future (projected) P/S of the market segment - Pharma immune
Precigen is a biotech company developing gene and cell therapies using its UltraCAR-T platform for the treatment of cancer and other diseases. This figure reflects its estimated future revenue. Its high valuation relative to its sector reflects confidence in its technology, which promises faster and cheaper production of CAR-T therapy, but carries high clinical risks.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772603671084 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Precigen is a biotech company developing gene and cell therapies for the treatment of cancer and autoimmune diseases. Its future depends on the success of its innovative UltraCAR-T platform. This chart of overall market expectations reflects investor appetite for high-risk but potentially revolutionary medical technologies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772603671226 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Precigen Inc.
Precigen is a biotech company at the forefront of gene and cell therapy. Its revenue currently comes not from drug sales, but from strategic partnerships and licensing agreements. This graph reflects payments received for reaching specific research milestones, confirming the value of its scientific platform.
Sales of companies in the market segment - Pharma immune
Precigen is a biotechnology company using synthetic biology approaches to develop gene and cell therapies. The company works in areas such as oncology and autoimmune diseases. This chart represents the total revenue of the entire advanced therapy market, illustrating the enormous potential for the breakthrough technologies Precigen is developing.
Overall market sales
Precigen, Inc. is a biotechnology company developing gene and cell therapies. Its value depends on progress in clinical development. Its business doesn't correlate with economic cycles, but the overall situation shown in this chart impacts the availability of capital to finance long-term and risky R&D projects that are vital to the company's future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Precigen Inc.
Precigen is a biotechnology company developing gene and cell therapies for the treatment of cancer and autoimmune diseases. Its future revenue depends on the success of clinical trials and the commercialization of its innovative platforms. This chart represents analysts' long-term view of the potential of its cutting-edge technologies.
%20sales%20of%20the%20company%20Precigen%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Precigen-Inc.&v=1772603671410 "Schedule of future (projected) sales of the company Precigen Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Precigen is a biopharmaceutical company developing gene and cell therapies. This forecast chart reflects potential future revenue from their therapeutic platforms, including UltraCAR-T. The data highlights which of their innovative approaches to treating cancer and autoimmune diseases analysts believe have the most potential for commercialization.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772603671466 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Precigen. The company develops gene and cell therapies. Its ability to fund cutting-edge research and bring products to market depends on capital inflows into the sector, which increase during periods of overall economic confidence and risk appetite.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772603671509 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Precigen Inc.
Precigen is a clinical-stage biotechnology company developing advanced cell and gene therapies. This chart reflects its focus on investing in science. Future profitability is entirely dependent on the success of its UltraCAR-T platform and other innovative approaches to treating cancer and other diseases.
Market segment marginality - Pharma immune
Precigen is a biotech company developing gene and cell therapies using its innovative UltraCAR-T platform. Future profitability depends on the success of its oncology programs in clinical trials. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential of Precigen's cutting-edge technologies.
Market marginality as a whole
Precigen is a biotech company developing gene and cell therapies. Its future depends on breakthroughs in research and the ability to fund expensive trials. This chart illustrates the market's overall risk appetite. During periods of economic growth, investors are more willing to invest in innovative but speculative biotech companies like Precigen.
Employees in the company, segment and market as a whole
Number of employees in the company Precigen Inc.
Precigen, Inc. is a biotechnology company developing gene and cell therapies. This chart reflects the size of its scientific team working on innovative treatments for cancer and autoimmune diseases. The dynamics show how the company manages its R&D resources, focusing on advancing its unique platforms through clinical trials.
Share of the company's employees Precigen Inc. within the market segment - Pharma immune
Precigen develops cutting-edge gene and cell therapy methods. Its UltraCAR-T platform promises to create personalized cancer treatments faster and more affordably. This chart shows the company's share of the total number of scientists working in cell therapy. It reflects its innovative potential and ambition to change the paradigm of cancer treatment.
Number of employees in the market segment - Pharma immune
Precigen, Inc. is a biopharmaceutical company developing gene and cell therapies using its innovative UltraCAR-T platform. This chart reflects activity in the immune-pharma sector. The growing number of scientists in this cutting-edge field reflects the intense race to create safer and more effective cancer treatments, a niche in which Precigen is seeking to carve out its niche.
Number of employees in the market as a whole
Precigen is a biotechnology company developing gene and cell therapies. Their future depends on the success of their innovative platform and clinical development. This general employment schedule is completely irrelevant to their operations. Hiring decisions are made solely based on scientific progress and clinical trial needs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Precigen Inc. (PGEN)
Precigen is a biotech company specializing in cell and gene therapy. Its valuation is based on the potential of its cutting-edge scientific platform. This chart for such companies typically shows a very high cost per employee, as investors value the intellectual property created by a small team of elite scientists.
%20of%20the%20company%20Precigen%20Inc.%20(PGEN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Precigen-Inc.-PGEN&v=1772603672111 "Chart of market capitalization per employee (in thousands of dollars) of the company Precigen Inc. (PGEN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Precigen (PGEN) is a biotech company using synthetic biology to develop cancer treatments (CAR-T) and gene therapy. Their value lies in their R&D platform, which reflects the high market valuation of their cutting-edge scientific research.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772603672200 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Precigen is a biotech company developing gene and cell therapies. Its market capitalization is based on the potential of its cutting-edge scientific platform. This metric represents a very high market value per employee, which is typical for biotech, where a small team of scientists is working to create revolutionary treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772603672313 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Precigen Inc. (PGEN)
Precigen (PGEN) is a biotech company using cutting-edge technologies (gene therapy) to treat cancer and autoimmune diseases. It's pure R&D. This chart doesn't show profit, but rather the company's "burn rate": how much the company invests (negative profit) per scientist to develop these breakthrough treatments.
%20Chart%20Precigen%20Inc.%20(PGEN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Precigen-Inc.-PGEN&v=1772603672373 "Company Profit Per Employee (in thousands of dollars) Chart Precigen Inc. (PGEN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Precigen is a clinical-stage biotech company developing gene and cell therapy (CAR-T) for cancer. This chart shows the benchmark for the "Biotech" sector. In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by "profit," but by the "burn rate" of the R&D budget.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772603672428 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Precigen (PGEN) is a biotech company working in gene and cell therapy. They use their platforms (such as UltraCAR-T) to create "living drugs" against cancer and autoimmune diseases. This is at the cutting edge of science. This chart helps us understand how the R&D model, where a handful of scientists create breakthrough treatments, compares in effectiveness to the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772603672498 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Precigen Inc. (PGEN)
Precigen is a biotech company developing gene and cell therapies. While in clinical development, it does not yet have stable commercial revenue from its products. This chart shows revenue from collaborations and licensing agreements, which are a vital source of funding for its cutting-edge research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Precigen-Inc.-PGEN&v=1772603672579 "Sales chart per company employee Precigen Inc. (PGEN)")
Sales per employee in the market segment - Pharma immune
Precigen (PGEN) is a biotech company working on cell and gene therapy. Their UltraCAR-T platform promises to create CAR-T therapy (for cancer treatment) faster and more affordably. This graph reflects their R&D status. The productivity of their scientific team lies in advancing this platform through clinical trials, not in ongoing sales.
Sales per employee for the market as a whole
Precigen (PGEN) is a biotech company developing gene and cell therapy platforms, including UltraCAR-T technology for cancer treatment. This is cutting-edge medicine. This chart is typical for a biotech company in the R&D stage. Revenue, if any, comes from partnerships, not sales. The entire scientific staff is focused on developing these complex therapies, and this metric reflects the intensity of investment in future breakthroughs.
Short shares by company, segment and market as a whole
Shares shorted by company Precigen Inc. (PGEN)
Precigen is a biotech company using its platforms (including its UltraCAR-T technology) to develop cell and gene therapies, primarily in oncology. This chart shows a high level of skepticism. "Bears" are betting that the company, despite years of promise, will fail to commercialize its complex technologies or that its clinical trials will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Precigen-Inc.-PGEN&v=1772603672729 "Short Shares Chart for the Company Precigen Inc. (PGEN)")
Shares shorted by market segment - Pharma immune
Precigen (PGEN) is a biotech company developing gene and cell therapies (including CAR-T) for the treatment of cancer and autoimmune diseases. This chart shows bets against the immune pharma sector. The shorts in this sector reflect investor skepticism toward early-stage platforms requiring massive investment and the intense competition in the CAR-T field.
Shares shorted by the overall market
Precigen is a biotech company working on cutting-edge cell and gene therapy. Its value is based on future expectations, not current profits. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like PGEN in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Precigen Inc. (PGEN)
Precigen is a biotech company focused on gene and cell therapy. The stock is highly speculative. This chart can surge above 70 on positive R&D news. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Precigen-Inc.-PGEN&v=1772603672932 "RSI 14 indicator chart for the company's stock Precigen Inc. (PGEN)")
RSI 14 Market Segment - Pharma immune
Precigen is a biotech company developing gene and cell therapy platforms. Its "UltraCAR-T" approach aims to create immunotherapy for cancer treatment. This chart shows the overall "temperature" in the volatile cell therapy and immuno-oncology sector. It helps separate PGEN's dynamics from the general hype or disillusionment in this field.
RSI 14 for the overall market
Precigen (PGEN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PGEN (Precigen Inc.)
Precigen (PGEN) is a biotech company developing cutting-edge cell and gene therapies. Its flagship platform is the UltraCAR-T, which enables the faster and more cost-effective development of CAR-T therapies for cancer treatment. This chart shows the average analyst forecast, reflecting their assessment of the clinical data and commercial potential of this innovative platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PGEN-Precigen-Inc.&v=1772603673085 "A chart showing analyst consensus forecasts for the expected stock price. PGEN (Precigen Inc.)")
The difference between the consensus estimate and the actual stock price PGEN (Precigen Inc.)
Precigen (PGEN) is a biotech company developing gene and cell therapy platforms. Its flagship product is UltraCAR-T, a technology that enables the rapid and cost-effective creation of CAR-T therapy. This chart shows the difference between the consensus forecast and the price, reflecting analysts' confidence in this high-risk R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PGEN-Precigen-Inc.&v=1772603673111 "A chart showing the difference between the consensus forecast and the actual stock price. PGEN (Precigen Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Precigen is a biotech company focused on gene and cell therapy. Its key asset is UltraCAR-T, a platform for rapidly "assembling" cancer-killing cells. This chart shows analysts' overall expectations for the immunotherapy sector, reflecting their belief in the commercialization of this complex technology.
Analysts' consensus forecast for the overall market share price
Precigen (PGEN) is a clinical-stage biotech developing gene and cell therapies. It's a risky R&D play. This chart of overall market sentiment is important. Optimism = the market is willing to burn cash funding unprofitable biotechs with high potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Precigen Inc.
Precigen (PGEN) is a biotech company developing gene and cell therapy platforms. Their approach (such as UltraCAR-T) aims to create faster and cheaper cancer treatments. This chart is a pure valuation of their R&D platform. Its performance is entirely dependent on their progress in clinical trials and their belief in their technological advantage.
AKIMA Market Segment Index - Pharma immune
Precigen (PGEN) is a clinical-stage biotech focused on gene therapy; the company develops innovative platforms (UltraCAR-T) to create next-generation cancer drugs. This summary metric evaluates its R&D. The graph shows the segment average. This benchmark provides insight into how this futuristic (R&D platform) model (PGEN) differentiates it from the average pharma company.
The AKIM Index for the overall market
Precigen is a biotech company developing gene and cell therapies for cancer and autoimmune diseases (UltraCAR-T platform). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story, undergoing transformation, fits into the context of overall economic trends.
